Despite ample experimental data indicating a role of inflammatory mediators in the behavioral and neurobiological manifestations elicited by exposure to physical and psychologic stressors, causative associations between systemic low-grade inflammation and central nervous system
inflammatory processes in posttraumatic stress disorder (PTSD) patients remain largely conceptual.
As in other stress-related disorders, pro-inflammatory activity may play an equivocal role in PTSD
pathophysiology, one that renders indiscriminate employment of anti-inflammatory agents of
questionable relevance. In fact, as several pieces of preclinical and clinical research convergingly sug-
gest, timely and targeted potentiation rather than inhibition of inflammatory responses may actually be
beneficial in patients who are characterized by suppressed microglia function in the face of systemic
low-grade inflammation. The deleterious impact of chronic stress-associated inflammation on the sy-
stemic level may, thus, need to be held in context with the – often not readily apparent – adaptive
payoffs of low-grade inflammation at the tissue level.